A woman born with almost no functional vision because of a genetic mutation has regained measurable sight after a single ...

The digital age has led to the explosive growth of data of all kinds. Traditional methods for storing data—such as hard drives—are beginning to face challenges due to limited storage capacities. With ...

Children as young as two with sickle cell disease can now receive a one-time CRISPR-based gene therapy after the FDA issued a ...

A research team from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences (CAS) has developed an analysis service platform called CRISPRimmunity, which was an interactive web ...

BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announce presentation of new data on exa-cel, ...

-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced ...

Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...

-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...

Analyst Salim Syed of Mizuho Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $82.00. Salim Syed has given his Buy rating due to a ...

CRISPR Therapeutics AG (NASDAQ:CRSP) reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease. The company disclosed data regarding the first 10 ...

Earlier this week, CRISPR Therapeutics AG drew attention as analysts projected an earnings per share of US$1.10 loss ...